DK1476468T3 - Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet - Google Patents

Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet

Info

Publication number
DK1476468T3
DK1476468T3 DK03705004T DK03705004T DK1476468T3 DK 1476468 T3 DK1476468 T3 DK 1476468T3 DK 03705004 T DK03705004 T DK 03705004T DK 03705004 T DK03705004 T DK 03705004T DK 1476468 T3 DK1476468 T3 DK 1476468T3
Authority
DK
Denmark
Prior art keywords
glycoprotein
directed against
neutralizing activity
monoclonal antibody
human monoclonal
Prior art date
Application number
DK03705004T
Other languages
Danish (da)
English (en)
Inventor
Roberto Burioni
Original Assignee
Roberto Burioni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Burioni filed Critical Roberto Burioni
Application granted granted Critical
Publication of DK1476468T3 publication Critical patent/DK1476468T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03705004T 2002-01-30 2003-01-29 Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet DK1476468T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
PCT/IT2003/000032 WO2003064473A2 (fr) 2002-01-30 2003-01-29 Fragments fab d'anticorps monoclonaux humains diriges contre la glycoproteine vhc/e2 et possedant une activite de neutralisation in vitro

Publications (1)

Publication Number Publication Date
DK1476468T3 true DK1476468T3 (da) 2009-01-19

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03705004T DK1476468T3 (da) 2002-01-30 2003-01-29 Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet

Country Status (17)

Country Link
US (2) US20050084845A1 (fr)
EP (1) EP1476468B9 (fr)
JP (1) JP4287280B2 (fr)
KR (1) KR101002791B1 (fr)
CN (1) CN1856508A (fr)
AT (1) ATE407147T1 (fr)
AU (1) AU2003208000B2 (fr)
CA (1) CA2474801C (fr)
DE (1) DE60323333D1 (fr)
DK (1) DK1476468T3 (fr)
EA (1) EA009861B1 (fr)
ES (1) ES2314179T3 (fr)
IT (1) ITRM20020049A1 (fr)
NZ (1) NZ534922A (fr)
RU (1) RU2004126238A (fr)
WO (1) WO2003064473A2 (fr)
ZA (1) ZA200406187B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
JP2010519916A (ja) * 2007-03-06 2010-06-10 リボバックス バイオテクノロジーズ ソシエテ アノニム 風疹ウイルスに特異的な抗体
AU2008280057A1 (en) 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Antibody having inhibitory activity on infection with hepatitis C virus (HCV), and use thereof
RU2462475C2 (ru) * 2007-12-17 2012-09-27 Медикал Рисерч Каунсил Текнолоджи Антитела против вируса гепатита с
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (fr) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. Utilisation d'un anticorps anti-vhc monoclonal humain en tant que médicament pour le traitement thérapeutique et la prévention d'infections par le vhc
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ITTO20080964A1 (it) * 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
JP6095984B2 (ja) 2010-03-01 2017-03-15 アニョロ, ヴィンセントAGNELLO, Vincent Ｈｃｖ感染患者のクリオグロブリン血症性血管炎およびｂ細胞悪性腫瘍のための予後マーカー
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
CN118440202A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
CN116963779A (zh) 2020-09-02 2023-10-27 国立大学法人东京大学 癌症免疫微环境的调节物质及其预防、诊断或治疗
US20250375498A1 (en) 2022-07-28 2025-12-11 The University Of Tokyo Neurotrimin function inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1097172A1 (fr) * 1998-07-21 2001-05-09 Genmab A/S Anticorps contre le virus de l'hepatite c et ses utilisations
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
WO2002005560A2 (fr) 2000-07-12 2002-01-17 General Instrument Corporation Procede et dispositif servant a telecharger des objets par l'intermediaire d'un canal en bande avec un impact minimum sur l'abonne
CA2429946A1 (fr) * 2000-12-01 2002-07-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Anticorps monoclonaux specifiques a la glycoproteine e2 du virus de l'hepatite c et leurs utilisations dans le diagnostic, le traitement et la prevention de l'hepatite c

Also Published As

Publication number Publication date
JP4287280B2 (ja) 2009-07-01
ZA200406187B (en) 2006-06-28
EP1476468B1 (fr) 2008-09-03
RU2004126238A (ru) 2005-04-20
ITRM20020049A0 (it) 2002-01-30
CA2474801C (fr) 2012-03-20
AU2003208000B2 (en) 2010-05-20
EP1476468A2 (fr) 2004-11-17
EA200401081A1 (ru) 2005-10-27
CN1856508A (zh) 2006-11-01
US20050084845A1 (en) 2005-04-21
KR101002791B1 (ko) 2010-12-21
DE60323333D1 (de) 2008-10-16
ITRM20020049A1 (it) 2003-07-30
NZ534922A (en) 2008-07-31
JP2005531286A (ja) 2005-10-20
US7727529B2 (en) 2010-06-01
CA2474801A1 (fr) 2003-08-07
WO2003064473A3 (fr) 2003-12-24
EA009861B1 (ru) 2008-04-28
KR20040077745A (ko) 2004-09-06
EP1476468B9 (fr) 2009-04-08
ES2314179T3 (es) 2009-03-16
US20080241162A1 (en) 2008-10-02
WO2003064473A2 (fr) 2003-08-07
ATE407147T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
DE60323333D1 (de) Fab-fragmente humaner monoklonaler antikörper mit protein
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
ATE549033T1 (de) Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
SI1615952T1 (sl) Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ECSP066379A (es) Anticuerpos rg1 y usos de los mismos
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
DK2126049T3 (da) Antistoffer mod humant cytomegalovirus (hCMV)
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
EE05474B1 (et) Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2006137938A3 (fr) Fragments d'anticorps assurant la protection contre l'infection par des pathogenes, methodes d'utilisation de ces derniers
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
EP1748075A4 (fr) Vaccin chimiokine-antigene recombinant
WO2007007160A3 (fr) Anticorps anti-madcam servant a traiter la fievre
WO2005049072A3 (fr) Vaccin therapeutique contre le cancer contenant des fragments de trag-3